DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Prader-Willi syndrome — screening already-approved drugs against its 47-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePrader-Willi syndrome maps to a 47-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for prader-willi syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
carbonic anhydrase 2 (CA2) — CA2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet hydroxymercurydrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3K34 · 0.9 Å · ligand 4-(HYDROXYMERCURY)BENZOIC ACID (HGB). Experimental structure, not a prediction.
What the evidence adds up to
Prader-Willi syndrome is a rare genetic disorder affecting endocrine, metabolic, and neurologic systems, producing multiple medical complications. Two literature reviews from 2019 and 2024 state the disease has no cure. The 2024 review says treatment should focus on neonatal feeding and growth, followed by hormonal therapy for hypothalamic dysfunction, and then prevention and treatment of obesity and its complications, requiring a comprehensive multidisciplinary approach. The 2019 review similarly concludes that early treatment can ensure greater comfort but does not alter the underlying condition.
A 2025 letter discusses two recent case reports of atypical deletions within the 15q11.2 region. It notes genetic and clinical complexity, urges caution when interpreting individual cases, and supports a symptom-based management approach. The letter calls for controlled experimental research to elucidate the regulatory landscape of the PWS locus.
No abstract reports any drug trial, any quantitative survival or response rate, or any specific pharmacological intervention. The evidence base consists entirely of clinical descriptions and management recommendations, with no controlled data on any drug.
What is still missing is any controlled trial of a repurposed drug, any funding for such a trial, and any patient stratification strategy that might identify subgroups responsive to a specific agent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
JAAPA · 2024 · 1 citations
A review of Prader-Willi syndrome
AbstractABSTRACT: Prader-Willi syndrome is a rare and complex genetic disorder with multiple physical and behavioral characteristics, affecting endocrine, metabolic, and neurologic systems and producing a plethora of medical complications. Early identification and diagnosis are paramount to providing timely and appropriate interventions to improve patient outcomes. Treatment should focus on neonatal feeding and growth, followed by hormonal therapy for hypothalamic dysfunction, and should then be directed at the prevention and treatment of obesity and obesity-related complications. Effective treatment requires a comprehensive multidisciplinary approach.
The American Journal of Gastroenterology · 2019 · 1 citations
PRADER WILLI SYNDROME: A LITERATURE REVIEW
AbstractObjective: To review articles and case reports on Prader-Willi Syndrome, observing its characteristics and relating its treatment to the various fields of health. Methodology: As a result of articles found in the following databases: PubMed, MedLine, SciELO and European journal of human genetic Results: SPW can be diagnosed in the neonatal period through genetic studies or physical characteristics, it is a disease that has no cure, but can be treated, preferably early, to ensure the greatest comfort to the patient during his life. Conclusion: Because it is a syndrome that affects the patient in behavioral, structural and intellectual environments, act jointly to ensure the well being of the individual with SPW.
Molecular Genetics & Genomic Medicine · 2025 · 0 citations · open access
Atypical Prader–Willi Syndrome Deletions: Insights Into the Complex Regulation and Phenotypic Variability
AbstractThis letter discusses two recent reports of Prader–Willi syndrome (PWS) cases with atypical deletions within the 15q11.2 region. The genetic and clinical complexity highlights the need for caution when interpreting individual cases, supports a symptom‐based management approach, and calls for controlled experimental research to elucidate the regulatory landscape of the PWS locus.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
